Company Overview

HeartSciences Inc. is a medical technology company focused on the development of artificial intelligence–enabled electrocardiogram (ECG) diagnostic solutions. The company operates within the medical devices and digital health industries, with a specific emphasis on improving the detection and assessment of structural heart disease and cardiac dysfunction using non-invasive tools. Its core strategy centers on applying advanced signal processing and machine learning techniques to standard ECG data to extract clinically actionable insights beyond traditional ECG interpretation.

The company’s primary products are based on its proprietary MyoVista® technology platform, which is designed to enhance ECG diagnostics for use in clinical and screening environments. HeartSciences primarily targets healthcare providers, including hospitals, cardiology clinics, and physicians, as well as broader population health and screening markets. Founded in 2007, the company evolved from early research into ventricular dysfunction detection and later transitioned into a publicly traded entity, focusing its development efforts on regulatory clearance and commercialization of AI-driven cardiac diagnostic software.

Business Operations

HeartSciences generates its business activity through the development, regulatory approval, and planned commercialization of ECG-based diagnostic software and related hardware solutions. Its core business units are centered on MyoVista® wavECG™ and MyoVista® Insights™, which apply machine learning algorithms to analyze high-fidelity ECG signals to identify markers associated with cardiac dysfunction. Revenue to date has been limited and primarily associated with development-stage activities rather than broad commercial sales.

The company operates primarily as a U.S.-based medical device developer, with research, regulatory, and corporate functions centralized in the United States. HeartSciences controls proprietary software algorithms, signal processing techniques, and associated intellectual property related to ECG enhancement. As of publicly available disclosures, the company does not report large-scale manufacturing operations and relies on external partners for certain development, testing, and regulatory processes. Data inconclusive based on available public sources regarding material joint ventures or long-term commercial distribution partnerships.

Strategic Position & Investments

HeartSciences’ strategic direction is focused on achieving broader regulatory clearances, expanding clinical validation, and advancing commercialization of its AI-based ECG technologies. Growth initiatives emphasize positioning MyoVista® as a cost-effective, non-invasive screening tool that can complement or precede more expensive cardiac imaging modalities such as echocardiography. The company has highlighted the potential use of its technology in early detection, population screening, and point-of-care diagnostics.

The company has historically pursued incremental investment in software development, clinical studies, and intellectual property rather than large-scale acquisitions. No significant acquisitions have been disclosed in recent public filings. HeartSciences’ technology strategy remains concentrated on machine learning–driven cardiac signal analysis, with an emphasis on expanding diagnostic indications over time. Data inconclusive based on available public sources regarding material equity investments or ownership of operating subsidiaries beyond its core operating entity.

Geographic Footprint

HeartSciences is headquartered in the United States, with its primary operational and corporate activities conducted domestically. Its regulatory focus has centered on the U.S. market, particularly engagement with the Food and Drug Administration for medical device clearance. The company has also indicated interest in international markets where ECG-based screening tools are widely used, though commercial penetration outside the United States remains limited.

Internationally, HeartSciences has referenced potential opportunities in Europe and other regions with established ECG infrastructure, but publicly available disclosures do not indicate material revenue generation or permanent operational facilities outside the United States. Data inconclusive based on available public sources regarding the scale and duration of any ongoing international commercialization activities.

Leadership & Governance

HeartSciences is led by an executive team with experience in medical devices, healthcare technology, and corporate finance. The company’s governance structure includes a board of directors overseeing strategic direction, regulatory progress, and capital markets activities. Leadership has consistently emphasized disciplined capital allocation, regulatory compliance, and the clinical validation of its AI-driven diagnostic technologies.

Key executives include:

• Andrew Simpson – Chief Executive Officer
• Robert Eno – Chief Financial Officer
• Dr. Richard Ferrier – Chief Technology Officer

Management’s stated strategic vision focuses on expanding access to advanced cardiac diagnostics through scalable, software-driven solutions while maintaining alignment with regulatory standards and clinical evidence requirements.